Get started
Author

Shun‐ichi Isa

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
2014 · Tomoya Kawaguchi, Masahiko Ando, et al. · Journal of Clinical Oncology · 260
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
2015 · Masaru Watanabe, Tomoya Kawaguchi, et al. · Clinical Cancer Research · 214
Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study
2016 · Tomoya Kawaguchi, Yasuhiro Koh, et al. · Journal of Clinical Oncology · 128
Pretreatment advanced lung cancer inflammation index ( ALI ) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
2017 · Takayuki Shiroyama, Hidekazu Suzuki, et al. · Cancer Medicine · 112
PDF
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled Analysis of the Literature
2013 · Kazuyuki Tsujino, Takayasu Kurata, et al. · Journal of Thoracic Oncology · 112
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
2018 · Motohiro Tamiya, Akihiro Tamiya, et al. · PLoS ONE · 97
PDF
Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study
2017 · AKIHIRO TAMIYA, MOTOHIRO TAMIYA, et al. · Anticancer Research · 88
PDF
Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials
2011 · Yoshikazu Hasegawa, Tomoya Kawaguchi, et al. · Journal of Thoracic Oncology · 66
The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials
2015 · Yoshikazu Hasegawa, Masahiko Ando, et al. · The Oncologist · 56
Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004
2009 · Shun-Ichi Isa, Tomoya Kawaguchi, et al. · Journal of Thoracic Oncology · 54
Human papilloma virus in non-small cell lung cancer in never smokers: A systematic review of the literature
2013 · Yoshikazu Hasegawa, Masahiko Ando, et al. · Lung Cancer · 53
Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer
2018 · TAKAYUKI SHIROYAMA, HIDEKAZU SUZUKI, et al. · Anticancer Research · 51
PDF
Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib
2009 · Kazuyuki Tsujino, Tomoya Kawaguchi, et al. · Journal of Thoracic Oncology · 41
PDF
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer
2017 · AKIHIRO TAMIYA, MOTOHIRO TAMIYA, et al. · Anticancer Research · 40
PDF
Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
2013 · Yoshio Okano, Masahiko Ando, et al. · Journal of Clinical Oncology · 39
Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
2019 · Keiko Nakao, Shinji Kobuchi, et al. · Scientific Reports · 35
PDF
Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR
2017 · Masaru Watanabe, Tomoya Kawaguchi, et al. · EBioMedicine · 18
PDF
Improvement of Mycobacterium abscessus Pulmonary Disease after Nivolumab Administration in a Patient with Advanced Non-small Cell Lung Cancer
2018 · Seigo Ishii, Akihiro Tamiya, et al. · Internal Medicine · 17
PDF
Impact of somatic mutations on prognosis in resected non‐small‐cell lung cancer: The Japan Molecular Epidemiology for lung cancer study
2020 · Akihiro Tamiya, Yasuhiro Koh, et al. · Cancer Medicine · 14
PDF
Malignant Pleural Effusion from Lung Adenocarcinoma Treated by Gefitinib
2011 · Akihito Kubo, Yasuhiro Koh, et al. · Internal Medicine · 13
PDF
Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes
2022 · Koichi Sato, Hiroaki Akamatsu, et al. · BMC Cancer · 12
PDF
Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab
2018 · KENJI NAKAHAMA, AKIHIRO TAMIYA, et al. · In Vivo · 11
PDF
The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter
2017 · KENJI NAKAHAMA, SHUN-ICHI ISA, et al. · Anticancer Research · 10
Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature.
2012 · Satomi Yamamoto, Kazuyuki Tsujino, et al. · Journal of Clinical Oncology · 10
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer
2024 · Akihiro Tamiya, Mitsuo Osuga, et al. · Lung Cancer · 9
PDF
Works count: 66
Citation count: 1,635
H-index: 17
I10-index: 24
Year
Topic
Type